Portfolio Choice  123    15   

Published: Aug 29, 2019
Updated: Aug 29, 2019

NEOGEN CHEMICALS
BSE ticker code 542665
NSE ticker code NEOGEN
Major activity Speciality Chemicals
Managing Director Haridas Thakarshi Kanani
Equity capital Rs. 23.34 crore; FV Rs. 10
52 week high/low Rs. 1380 / Rs. 600
CMP Rs. 1259.90
Market Capitalisation Rs. 2939.93 crore
Recommendation Buy at declines
Pole player in speciality chem

Neogen Chemicals is a leading manufacturer of speciality chemicals based on bromine and lithium. Starting in 1991 at Mhape in Navi Mumbai with the manufacture of a few bromine and lithium compounds, the company has during the last three decades expanded its range of products to around 200 today, comprising 182 organic and 19 inorganic chemicals. In addition, the company also undertakes custom synthesis and contract manufacturing of speciality chemicals. Its prospects going ahead are exciting.

Consider:

  • z Neogen is a leading speciality chemicals company and this industry segment is offering multifold returns to investors. Share prices of almost all speciality companies are at sky-high levels and prospects for this segment are highly promising. Till a couple of years ago, China was the uncrowned king in supplying speciality chemicals to global consumers. But on account of a stiff environmental-friendly policy of the Beijing government, there has been a sharp fall in production by Chinese companies. At the same time, global chemical players have felt the need to diversify the sources of imports and have started adopting a ‘China plus one’ policy to meet their requirements. India, thanks to its excellent quality of products and manufacturing competitiveness, has emerged as a leading alternative supplier of speciality chemicals to global consumers. According to experts, the unprecedented boom in speciality chemicals will continue unabated till at least 2027. In short, the outlook for Neogen is bullish at present.
  • z The company operates from two modern manufacturing facilities — at Mhape in Navi Mumbai of Maharashtra and at Karhadi in Vadodara of Gujarat. Neogen has set up a third greenfield manufacturing facility at Dahej in Gujarat, which has recently gone on stream. At the same time, the company has also embarked upon an expansion plan for the Vadodara plant. These additional capacities will give a big boost to the company’s topline as well as bottomline at a time when the demand for its products is steadily on the rise.
  • z Three decades ago, the company had started with 4 to 5 products, which went up to 20 products by 2001, and the current product portfolio is around 200. At the same time, the company’s customer base is also on the rise and has by now reached to 1,363, of which about 1,237 are domestic customers and 126 international customers. These customers are spread across a wide array of application industries, including pharmaceuticals, agrochemicals, aroma chemicals, electrical chemicals, speciality polymers, construction chemicals and VAM original equipment manufacturers. Among the major customers are Austin Chemical of the US, CBC of Japan, and DIVI’s Laboratories, Laurus Labs, Solway Specialities India, Thermal and Voltas – all of India. The number of customers is on the rise.
  • z Besides expanding its manufacturing and marketing its speciality chemicals products, the company has planned to increase the size and scale of its contract research and manufacturing business over the next few years and is in discussions with various companies in Europe and Japan to develop their proprietary products, for which the company has already executed non-disclosure and secrecy agreements.
  • z Neogen’s finances are growing steadily. During the last five years, its sales turnover has expanded from Rs 121 crore in fiscal 2021 with the profit at net level shooting up from Rs 7.75 crore to Rs 31.44 crore during this period. The company’s financial position is getting stronger by the day. As on March 31, 2021, its reserves stood at Rs 133.40 crore, almost six times its equity capital of Rs. 23.33 crore. Prospects ahead are very bright and we expect an EPS of Rs 20 within a couple of years.

PERFORMANCE INDICATORS (Rs. in crore)

Year Net Sales Net Profit EPS (Rs.) Div (%) BV (%) RONW (%)
2018-19 239.10 21.00 9.00 15.0 60.70 34.80
2019-20 306.10 28.70 12.30 20.0 67.00 25.30
2020-21(E) 336.42 31.33 13.40 23.0 78.40 18.47
2021-22(E) 412.40 35.46 15.21 25.0 81.10 20.15
INDO AMINES LTD
BSE ticker code 524648
NSE ticker code --
Major activity Commodity Chemicals
Chairman Vijay Palkar
Equity capital Rs. 35.35 crore; FV Rs. 10
52 week high/low Rs. 375 / Rs. 49
CMP Rs. 254.00
Market Capitalisation Rs. 897.86 crore
Recommendation Buy at declines
Riding speciality chem demand

Indo Amines is one of India’s largest manufacturers of organic and inorganic chemical compounds. To be specific, it manufactures fine, speciality and performance chemicals, providing a package of products and technical services for the domestic and global markets. The company also manufactures perfumery chemicals and active pharmaceutical ingredients. Prospects for the company are highly promising.

Consider:

  • z The company is one of India’s largest manufacturers of various amino acids, biogenic amines, trimethylamine and aniline. The company’s products are being used in several industries, including agrochemicals, fertilisers, pesticides, petrochemicals, dyes and intermediates, and road construction companies. Thus, the business prospects for the company are quite encouraging.
  • z Indo Amines strives to be a best-in-class chemical manufacturing company by adopting an innovation approach with great technical competency. The company has ten state-of-the-art manufacturing facilities, with four new sites under construction. The Department of Scientific and Industrial Research has already approved the company’s R&D laboratory. Here, the company strives to develop new products among fine chemicals, alcohols, cycloalkanes, amine hydrochlorides, etc. A few years ago, the company received approval for 10 speciality chemicals from a US environment body. This approval has pushed up the demand for these products immensely in the American market.
  • z Needless to say, the company’s financial performance is growing steadily. During the last five years, its sales turnover (standalone) has expanded from Rs 279 crore in fiscal 2017 to Rs 539 crore – almost double – with the profit at net level shooting up from Rs 14 crore to Rs 33 crore during this period. The company’s financial position is improving steadily, with reserves at the end of March 2021 standing at Rs 124 crore as against its equity capital of Rs 35.35 crore. This is virtually a debt-free company with its interest burden for the year ended March 2021 being negligible at Rs 3.74 crore.
  • z India’s chemical industry is on the fast track due to the steady disappearance of China from the global export scene. Growing environmental concerns in China and a government crackdown there on chemical manufacturers have brought down China’s exports of chemicals, opening the global market for countries like India. Again, the demand for speciality chemicals is on the rise in international markets and Indian companies like Indo Amines have started manufacturing speciality chemicals of topmost quality. Indo Amines has been steadily raising its exports. At the same time, global consumers, concerned over China’s role in spreading the coronavirus, have started adopting a ‘China plus one’ policy in order not to depend on China alone for the supply of chemicals. This development has given a big boost to speciality chemicals companies in India like Indo Amines.

As expected, the company has started the new fiscal year (2022) on a buoyant note with sales in Q1FY22 jumping by almost 72 per cent to Rs 183 crore and net profit inching up by over 24 per cent to Rs 8.48 crore. Prospects for the period going ahead are considered all the better as the global demand for Indian speciality chemicals is steadily going up. During the last one year, the stock price has multiplied by over 5 times – from around Rs 50 to Rs 270. There is still some steam left. Buy at every decline.

CONSOLIDATED PERFORMANCE INDICATORS (Rs. in crore)

Year Net Sales Net Profit EPS (Rs.) Div (%) BV (%) RONW (%)
2018-2019 470.90 22.70 6.80 10.0 29.90 26.60
2019-2020 478.75 12.81 3.60 10.0 37.80 27.45
2020-2021(E) 540.43 37.41 10.60 11.0 45.70 25.55
2021-2022(E) 576.15 39.10 12.11 12.0 48.10 26.40
ORIENT PAPER
BSE ticker code 502420
NSE ticker code ORIENTPPR
Major activity Paper & Paper Products
Managing Director Manohar Lal Pachisia
Equity capital Rs. 21.22 crore; FV Re. 01
52 week high/low Rs. 34 / Rs. 15
CMP Rs. 29.20
Market Capitalisation Rs. 619.58 crore
Recommendation Buy at declines
Rs 225 crore capex will boost RoCE

Orient Paper and Industries, a CK Birla group company, is a leading manufacturer of paper with a capacity of 105 ktpa, of which printing and writing paper accounts for 55 ktpa and tissue paper 50 ktpa. The company is doing well and its prospects going ahead are all the more promising.

Consider:

  • z With its 50 ktpa capacity, Orient is the largest producer of tissue paper in the country. Today, tissue paper has emerged as the fastest growing segment in the country, growing at a rate of 12 per cent per annum – almost double the size of the paper industry which is growing at a rate of 6 per cent. With growing incomes, improving standards of living and increasing hygiene awareness, and growing export demand for Indian products, the prospects for the tissue paper segment are steadily improving.
  • z Global demand for Indian tissue paper is growing as pulp prices have spurted globally while in India they are on the decline. These opposite trends in the prices of the raw material for paper have boosted global demand for Indian tissue paper. And though a late entrant, OPIL has already cornered almost 47 per cent of the export market and its share continues to grow.
  • z There has been a marked drop in demand for paper during the pandemic period. But the re-opening of schools and colleges is expected to revive demand for writing and printing paper. According to the management of the company, demand for writing and printing paper had turned slack on account of closure of educational institutions and offices, forcing the company to run its machines for W&P paper at 70-75 per cent capacity. With the impact of the pandemic receding, and with schools and colleges reopening, demand for this paper segment has started reviving, more so when viewed in the context of the New Education Policy.
  • z Going ahead, the company’s profitability is expected to rise on account of: (a) ramping up its new tissue paper production to full capacity; (b) improved realisations due to firm global pulp prices and a weak rupee vis-à-vis weak raw material costs due to the increased focus on the farm forestry programme; (c) a better product mix with tissue paper’s revenue share slated to improve from 33-42 per cent in fiscal 2020 to around 50 per cent in fiscal 2023, and (d) benefits accruing from operating leverage. The company’s RoCE (return on capital employed) is projected to improve from 26 per cent in fiscal 2020 to 30 per cent in the fiscal 2023.
  • z The company has planned to enhance its pulp capacity from 72.5 ktpa to 100 ktpa, in order to eliminate its reliance on market pulp, at a cost of Rs 75 crore and by setting up a new recovery boiler at a cost of Rs 150 crore. Despite this capex, the company’s balance sheet will remain light and comfortable as the capex would be funded out of internal accruals and/or divestment of the company’s stake in Century Textile and Industries. And the company will generate an RoCE of around 20 per cent for the new tissue paper facility due to the new capex on brownfield expansion. The company would now enhance its tissue paper capacity by 25 ktpa at a minimal cost in future due to a huge land bank at its existing site as well as surplus power capacity.

The stock is available at an attractive price. Investment in this scrip will enable a shareholder to reap rich benefits in the long term.

PERFORMANCE INDICATORS (Rs. in crore)

Year Net Series Net Profit EPS (Rs.) Div (%) BV (%) RONW (%)
2018-19 710.00 84.30 4.00 110.0 63.20 8.00
2019-20 606.56 20.01 0.90 50.0 51.40 1.84
2020-21(E) 443.36 -46.55 -- 25.0 49.10 -
2021-22(E) 590.40 10.32 -- 25.0 50.30 1.11

February 15, 2025 - First Issue

Industry Review

VOL XVI - 10
February 01-15, 2025

Formerly Fortune India Managing Editor Deven Malkan Assistant Editor A.K. Batha President Bhupendra Shah Circulation Executive Warren Sequeira Art Director Prakash S. Acharekar Graphic Designer Madhukar Thakur Investment Analysis CI Research Bureau Anvicon Research DD Research Bureau Manager (Special Projects) Bhagwan Bhosale Editorial Associates New Delhi Ranjana Arora Bureau Chief Kolkata Anirbahn Chawdhory Gujarat Pranav Brahmbhatt Bureau Cheif Mobile: 098251-49108 Bangalore Jaya Padmanabhan Bureau Chief Chennai S Gururajan Bureau Chief (Tamil Nadu) Ludhiana Ajitkumar Vijh Bhubaneshwar Braja Bandhu Behera

Want to Subscribe?


Lighter Vein

Popular Stories

E-Waste Dilemma Tackling E-Waste Via Reverse Logistics, By Vihaan Shah

A modern-day enigma and a ramification of humanity's never-ending advancements, e-waste refers to the scum con- cealed by the outward glow of ever-advancing technology.

Archives

About Us    Contact Us    Careers    Terms & Condition    Privacy Policy

Liability clause: The investment recommendations made here are based on the personal judgement of the authors concerned. We do not accept liability for any losses that might occur. All rights reserved. Reproduction in any manner, in whole or in part, in English or in any other language is prohibited.

Copyright © 1983-2025 Corporate India. All Rights Reserved.

www.corporateind.com | Cookie Policy | Disclaimer